View Older Stories View More Recent Stories

Aug 24, 2021 07:00AM Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration
Aug 20, 2021 07:02AM Regeneron (REGN) Announces UK Authorizes its Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
Aug 20, 2021 07:00AM UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
Aug 5, 2021 06:30AM Regeneron Reports Second Quarter 2021 Financial and Operating Results
Aug 5, 2021 06:04AM Regeneron (REGN) Phase 3 Trial of Libtayo® Stopped Early Due to Significant Improvement in Overall Survival
Aug 5, 2021 06:00AM Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Aug 5, 2021 06:00AM Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Aug 4, 2021 05:06PM Regeneron (REGN) Announces NEJM Publishes Positive Phase 3 Trial Results for REGEN-COV to Prevent SARS-CoV-2 Infection
Aug 4, 2021 05:05PM New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
Aug 3, 2021 07:00AM Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation
Jul 30, 2021 01:47PM Regeneron (REGN) Says FDA Expands Use of REGEN-COV
Jul 30, 2021 01:45PM FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)
Jul 29, 2021 01:00AM Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients  
Jul 29, 2021 12:59AM Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients
Jul 27, 2021 07:11AM Regeneron (REGN), AstraZeneca (AZN) to Research, Develop and Commercialize New Small Molecule Medicines for Obesity
Jul 27, 2021 07:00AM Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity
Jul 20, 2021 01:00AM Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
Jul 7, 2021 04:15PM Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021
Jul 1, 2021 02:05PM Regeneron (REGN) Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
Jul 1, 2021 02:05PM Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
Jun 28, 2021 06:08AM Intellia Therapeutics (NTLA), Regeneron (REGN) Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy f
Jun 28, 2021 01:00AM Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
Jun 28, 2021 12:59AM Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis
Jun 26, 2021 11:16AM Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR)
Jun 26, 2021 11:15AM Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR)
Jun 26, 2021 11:15AM Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR)
Jun 25, 2021 06:23AM Regeneron (REGN), Sanofi (SNY) Announce Libtayo Approved by European Commission as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Jun 25, 2021 01:15AM Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Jun 25, 2021 01:15AM Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Jun 25, 2021 01:00AM Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
Jun 25, 2021 01:00AM Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression
Jun 22, 2021 04:15PM Regeneron to Participate in Guggenheim Biopharma Strategy Series
Jun 16, 2021 06:16AM Regeneron (REGN) REGEN-COV Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Jun 16, 2021 01:00AM REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Jun 14, 2021 08:03AM Twist Bioscience Corporation (TWST) Collaborates with Regeneron (REGN) for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening
Jun 14, 2021 08:01AM Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening
Jun 4, 2021 07:04AM Regeneron (REGN) Announces FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV Antibody Cocktail to Treat Patients with COVID-19
Jun 4, 2021 07:00AM FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19
May 25, 2021 04:15PM Regeneron Announces Investor Conference Presentations
May 24, 2021 06:15AM Regeneron (REGN) Announces Libtayo Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
May 24, 2021 01:02AM Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
May 21, 2021 11:45AM Teen Scientists and Engineers Win $5 Million at Largest Global High School STEM Competition
May 19, 2021 05:00PM Libtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse Cancers
May 17, 2021 10:01AM Regeneron (REGN), Sanofi (SNY) pivotal data at ATS 2021 show Dupixent significantly reduced asthma attacks and improved lung function in children
May 17, 2021 10:01AM Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
May 17, 2021 10:00AM Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children
May 17, 2021 09:59AM Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children
May 12, 2021 01:30PM Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary
May 10, 2021 06:13AM Checkmate Pharmaceuticals (CMPI) Announces Clinical Supply Agreement with Regeneron (REGN) to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo
May 6, 2021 06:30AM Regeneron Reports First Quarter 2021 Financial and Operating Results
View More Recent Stories View Older Stories